The Journal of Immunology, Vol 132, Issue 1 187-190, Copyright © 1984 by American Association of Immunologists

ARTICLES

Suppression of murine lupus nephritis by administration of an anti- idiotypic antibody to anti-DNA

BH Hahn and FM Ebling

The suppression of pathogenic antibodies to DNA in NZB/NZW f1 female mice was achieved by repeated inoculation of the mice with a monoclonal anti-idiotypic antibody (anti-Id). The anti-Id, an IgG1, kappa, was directed against a major cross-reactive idiotype (Id) on NZB/NZW IgG antibodies to DNA. One hundred micrograms of the anti-Id were inoculated i.p. every 2 wk, beginning at 6 wk of age (nondiseased mice-- no circulating anti-DNA or proteinuria) or 20 wk of age (diseased mice-- all with circulating anti-DNA, one-third with proteinuria). As controls, littermates received an IgG, kappa non-DNA-binding myeloma or no treatment. In the young mice, nephritis and anti-DNA antibodies appeared at the same time in all groups, and their circulating antibodies to DNA did not bear the target Id. In the older (20-wk-old) mice, survival was significantly prolonged because of delay in the onset of nephritis; the total quantities of antibodies to DNA were diminished, and the target Id, initially present on circulating IgG, was deleted. These benefits were transient; the suppression of antibodies was followed by the appearance of large quantities of anti- DNA that did not bear the major Id. Therefore, although administration of anti-Id was effective in reducing an undesirable antibody response after the target Id was present on circulating antibodies, the benefits were limited, probably by Id "switch" or by increased synthesis of pathogenic antibodies bearing a minor Id.

This article has been cited by other articles:

				Y. Shoenfeld, L. Rauova, B. Gilburd, F. Kvapil, I. Goldberg, J. Kopolovic, J. Rovensky, and M. Blank Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus Int. Immunol., November 1, 2002; 14(11): 1303 - 1311. [Abstract] [Full Text] [PDF]

				D Verthelyi, N Dybdal, K A Elias, and D M Klinman DNAse treatment does not improve the survival of lupus prone (NZB6NZW)F1 mice Lupus, May 1, 1998; 7(4): 223 - 230. [Abstract] [PDF]

				W M Williams and D A Isenberg Naturally occurring anti-idiotypic antibodies reactive with anti-DNA antibodies in systemic lupus erythematosus Lupus, March 1, 1998; 7(3): 164 - 175. [Abstract] [PDF]

				S. Coutts, M. Plunkett, G. Iverson, P. Barstad, and C. Berner Pharmacological intervention in antibody mediated disease Lupus, April 1, 1996; 5(2): 158 - 159. [Abstract] [PDF]

				W.M. Williams, N.A. Staines, S. Muller, and D.A. Isenberg Human T cell responses to autoantibody variable region peptides Lupus, December 1, 1995; 4(6): 464 - 471. [Abstract] [PDF]

				J. Kalsi, C. Ravirajan, H. Wiloch-Winska, F. Blanco, C. Longhurst, W. Williams, C. Chapman, J. Hillson, P. Youniou, D. Latchman, et al. Analysis of three new idiotypes on human monoclonal autoantibodies Lupus, October 1, 1995; 4(5): 375 - 389. [Abstract] [PDF]

				N.A. Staines, C.T. Ravirajan, A. Morgan, A.J. Belcher, A.J. Henry, R.A. Lake, D.A. Smith, A.S. Hamblin, M. Hara, D. Adu, et al. Expression and Relationships of Seven Public Idiotypes of DNA-Binding Autoantibodies on Monoclonal Antibodies and Serum Immunoglobulins Lupus, February 1, 1993; 2(1): 25 - 33. [Abstract] [PDF]

				N. A. Granholm and T. Cavallo Autoimmunity, Polyclonal B-Cell Activation and Infection Lupus, February 1, 1992; 1(2): 63 - 74. [Abstract] [PDF]